background
year
sinc
first
case
middl
east
respiratori
syndrom
coronaviru
infect
merscov
record
specif
treatment
investig
random
clinic
trial
result
vitro
anim
studi
suggest
combin
lopinavirritonavir
may
effect
merscov
aim
studi
investig
efficaci
treatment
combin
lopinavirritonavir
recombin
provid
standard
support
care
compar
treatment
placebo
provid
standard
support
care
patient
laboratoryconfirm
mer
requir
hospit
admiss
protocol
prepar
accord
spirit
standard
protocol
item
recommend
intervent
trial
guidelin
hospit
adult
patient
laboratoryconfirm
mer
enrol
recurs
twostag
group
sequenti
multicent
placebocontrol
doubleblind
random
control
trial
trial
initi
design
includ
twostag
compon
first
twostag
compon
design
adjust
sampl
size
determin
futil
stop
efficaci
stop
second
twostag
compon
design
determin
efficaci
stop
possibl
readjust
sampl
size
primari
outcom
mortal
sinc
first
report
infect
middl
east
respiratori
syndrom
coronaviru
merscov
publish
world
health
organ
notifi
laboratoryconfirm
infect
merscov
countri
least
report
death
case
fatal
specif
therapi
proven
efficaci
avail
potenti
treatment
test
random
clinic
trial
rct
evalu
base
result
vitro
anim
studi
merscov
infect
guanosin
analog
ribavirin
combin
interferon
alpha
use
treat
patient
mer
howev
concentr
ribavirin
requir
inhibit
merscov
vitro
exce
peak
level
blood
therapeut
dose
human
furthermor
retrospect
studi
combin
ribavirin
shown
clear
benefit
patient
mer
merscov
attenu
interferon
ifn
respons
innat
immun
system
mechan
thought
impair
antivir
adapt
type
thelper
cell
immun
respons
vitro
inhibitori
effect
merscov
close
relat
coronaviru
sever
acut
respiratori
syndrom
sar
cov
merscov
appear
significantli
sensit
sarscov
ifn
effect
among
ifn
subtyp
caus
greatest
vitro
inhibit
merscov
significantli
lower
ratio
halfmaxim
effect
concentr
ec
maxim
plasma
concentr
ec
c
max
indic
potenti
greater
efficaci
observ
may
also
partial
explain
lack
clear
benefit
associ
use
combin
ribavirin
recombin
bayer
leverkusen
germani
approv
multipl
sclerosi
base
vitro
data
combin
lopinavir
ritonavir
consid
candid
therapi
mer
lopinavir
ritonavir
antiretrovir
proteas
inhibitor
use
combin
treatment
human
immunodefici
viru
hiv
infect
limit
side
effect
combin
lopinavirritonavir
abbott
laboratori
chicago
il
usa
also
use
treatment
sar
one
studi
combin
lopinavirritonavir
use
patient
sar
associ
significantli
fewer
advers
clinic
outcom
acut
respiratori
distress
syndrom
death
day
onset
symptom
compar
ribavirin
alon
use
histor
control
versu
p
howev
histor
natur
control
comparison
allow
valid
estim
efficaci
highthroughput
screen
antivir
compound
lopinavir
inhibit
replic
merscov
level
occur
circul
singl
oral
dose
lopinavirritonavir
mg
lopinavir
mg
ritonavir
suggest
drug
achiev
therapeut
level
vivo
effect
lopinavirritonavir
mycophenol
mofetil
mmf
shown
viral
inhibitori
effect
vitro
test
common
marmoset
sever
merscov
infect
anim
treat
lopinavirritonavir
improv
clinic
radiolog
patholog
viralload
outcom
compar
untreat
anim
contrast
treatment
mmf
result
sever
fatal
diseas
higher
mean
viral
load
untreat
anim
untreat
anim
mmftreat
anim
mortal
h
compar
among
anim
treat
lopinavirritonavir
one
case
korean
mer
outbreak
lopinavirritonavir
use
combin
ribavirin
result
defervesc
virolog
clearanc
surviv
anoth
case
greec
lopinavirritonavir
combin
ifn
ribavirin
start
day
mer
ill
follow
day
later
clearanc
viremia
although
viral
ribonucl
acid
rna
persist
respiratori
secret
fourth
week
ill
patient
subsequ
die
korean
outbreak
mer
patient
develop
respiratori
ill
receiv
tripl
antivir
therapi
compos
pegyl
interferon
ifn
ribavirin
lopinavirritonavir
howev
data
efficaci
approach
lack
find
togeth
avail
safeti
profil
lopinavirritonavir
suggest
combin
agent
potenti
efficaci
treatment
patient
mer
object
miracl
trial
merscov
infect
treat
combin
lopinavirritonavir
assess
efficaci
administ
combin
lopinavirritonavir
recombin
hospit
adult
laboratoryconfirm
mer
studi
design
recurs
twostag
group
sequenti
multicent
random
placebocontrol
doubleblind
trial
report
studi
protocol
accord
spirit
standard
protocol
item
recommend
intervent
trial
templat
studi
recurs
twostag
group
sequenti
multicent
random
placebocontrol
doubleblind
trial
trial
initi
design
twostag
compon
two
interim
analys
one
final
analysi
first
twostag
compon
design
adjust
sampl
size
determin
futil
stop
efficaci
stop
second
twostag
compon
design
determin
efficaci
stop
possibl
readjust
sampl
size
maintain
condit
power
final
analysi
inclus
criteria
elig
assess
adult
defin
year
age
laboratori
confirm
merscov
infect
reversetranscript
polymeras
chain
reaction
rtpcr
diagnost
sampl
sourc
new
organ
dysfunct
judg
relat
mer
includ
hypoxia
defin
requir
supplement
oxygen
maintain
oxygen
satur
hypotens
systol
blood
pressur
mmhg
need
vasopressor
inotrop
medic
renal
impair
increas
creatinin
baselin
glomerular
filtrat
rate
reduct
baselin
urin
output
mlkg
hrisk
stage
rifl
criteria
neurolog
patholog
reduct
glasgow
coma
scale
ie
lower
point
thrombocytopenia
plateletsmm
gastrointestin
symptom
requir
hospit
eg
sever
nausea
vomit
diarrhea
orand
abdomin
pain
exclus
criteria
elig
assess
suicid
ideat
base
histori
contraind
known
allergi
hypersensit
reaction
lopinavirritonavir
recombin
includ
limit
toxic
epiderm
necrolysi
stevensjohnson
syndrom
erythema
multiform
urticaria
angioedema
elev
alanin
aminotransferas
alt
fivefold
upper
limit
hospit
laboratori
use
medic
contraind
lopinavirritonavir
replac
stop
studi
period
inhibitor
see
tabl
pregnancyelig
consent
femal
particip
childbear
age
test
pregnanc
enrol
studi
known
hiv
infect
concern
develop
resist
lopinavirritonavir
use
without
combin
antihiv
drug
patient
like
transfer
nonparticip
hospit
within
h
inform
consent
obtain
elig
patient
substitut
decisionmak
patient
lack
decisionmak
capac
patient
provid
inform
consent
randomli
alloc
one
two
studi
group
intervent
group
receiv
standard
care
well
lopinavirritonavir
recombin
lopinavirritonavir
lopinavir
mg
ritonavir
administ
everi
h
day
tablet
form
patient
unabl
take
medic
mouth
lopinavirritonavir
lopinavir
mg
mg
ritonavir
administ
suspens
everi
h
day
via
preexist
newli
place
nasogastr
tube
administ
subcutan
inject
altern
day
day
total
seven
dose
control
group
receiv
standard
care
well
placebo
treatment
day
frequenc
intervent
group
maintain
blind
one
placebo
given
everi
h
compris
sucros
tablet
capsul
ml
normal
salin
via
nasogastr
tube
patient
unabl
take
medic
mouth
patient
control
group
receiv
ml
normal
salin
subcutan
inject
altern
day
patient
studi
arm
receiv
standard
support
care
eg
oraland
intraven
administ
fluid
accord
basal
daili
requir
blood
pressur
support
oral
parenter
nutrit
venou
thromboembol
prophylaxi
antibiot
therapi
infect
supplement
oxygen
mechan
ventil
hypoxia
ventil
need
discret
treat
team
recommend
regard
current
standard
care
consist
best
clinic
practic
world
health
organ
guidelin
provid
treat
team
data
use
antimicrobi
corticosteroid
aspect
respiratori
cardiovascular
renal
support
collect
protocol
patient
test
hiv
enrol
howev
result
test
may
delay
h
patient
therefor
delay
random
wait
hiv
statu
patient
discov
hiv
posit
intervent
discontinu
outcom
data
collect
per
protocol
patient
includ
intentiontotreat
analysi
separ
ontreat
analysi
includ
patient
treatment
hiv
infect
per
treat
team
patient
randomli
assign
one
two
intervent
arm
variables
block
computergener
random
procedur
ensur
two
arm
contain
equal
number
patient
random
stratifi
accord
center
accord
whether
patient
requir
mechan
ventil
invas
noninvas
time
enrol
patient
alloc
follow
conceal
process
use
seal
fulli
opaqu
number
envelop
intervent
blind
research
team
princip
investig
coinvestig
research
coordin
steer
committe
treat
team
physician
bedsid
nurs
clinic
pharmacist
outcom
assessor
includ
laboratori
personnel
studi
patient
pharmacist
prepar
studi
medic
dose
nurs
administ
medic
studi
statistician
blind
approach
chosen
placebo
exactli
match
medic
appear
avail
lopinavirritonavir
recombin
store
secur
area
pharmaci
room
tempratur
refriger
accord
standard
hospit
procedur
product
monograph
temperatur
log
daili
minimum
maximum
temperatur
read
kept
site
pharmacist
temperatur
excurs
report
immedi
unblind
project
offic
sponsor
king
abdullah
intern
medic
research
center
riyadh
saudi
arabia
sodium
chlorid
ampoul
starch
capsul
store
restrict
area
room
temperatur
patient
random
site
investig
appropri
deleg
studi
personnel
seal
envelop
contain
patient
alloc
deliv
pharmaci
unblind
pharmacist
open
envelop
dispens
studi
drug
tamperproof
seal
box
blind
treatment
assign
seal
opaqu
box
label
includ
follow
inform
name
number
clinic
trial
protocol
patient
studi
number
site
number
box
open
unblind
studi
nurs
unblind
dose
nurs
respons
direct
clinic
care
patient
studi
procedur
includ
assess
studi
outcom
administ
treatment
second
unblind
nurs
check
treatment
regimen
patient
accord
local
hospit
regul
medic
administr
dose
nurs
maintain
blind
follow
measur
pull
screen
around
patient
bed
area
dose
administ
ensur
member
treat
team
present
discard
label
use
syring
way
ensur
ident
medic
reveal
avoid
discuss
regard
studi
drug
hospit
staff
except
unblind
pharmacist
studi
intervent
continu
day
accord
protocol
medic
discontinu
patient
well
enough
discharg
hospit
even
occur
day
elaps
frequenc
durat
followup
patient
follow
daili
discharg
hospit
day
whichev
come
first
fig
day
patient
follow
document
icu
hospit
mortal
length
stay
collect
inform
may
requir
telephon
interview
patient
next
kin
figur
show
schedul
enrol
intervent
assess
miracl
trial
accord
spirit
templat
spirit
checklist
given
addit
file
diagnost
rtpcr
preform
per
hospit
protocol
hospit
laboratori
fig
schedul
enrol
intervent
assess
miracl
trial
accord
standard
protocol
item
recommend
intervent
trial
spirit
templat
arrow
indic
period
continu
daili
collect
assess
wherea
x
indic
collect
specif
day
day
except
assess
clinic
pharmacist
test
sputum
tracheal
aspir
broncheoalveolar
lavag
nasopharyng
swab
continu
twice
weekli
two
consecut
test
neg
icufre
day
number
day
patient
care
icu
first
day
enrol
patient
die
within
day
assign
valu
b
hospit
length
stay
calcul
number
day
admiss
discharg
hospit
compet
risk
effect
death
length
stay
length
stay
also
report
survivor
alon
secondari
laboratori
outcom
viral
replic
kinet
calcul
determin
viral
rna
load
reflect
c
valu
semiquantit
pcr
serial
sampl
upper
lower
respiratori
tract
secret
blood
collect
twice
per
week
quantit
pcr
may
sensit
c
valu
use
becom
avail
trial
time
clearanc
lower
respiratori
tract
determin
result
rtpcr
analys
lower
respiratori
tract
secret
nasopharyng
swab
nonintub
patient
unabl
give
sputum
sampl
clearanc
defin
two
neg
rtpcr
result
follow
posit
one
patient
die
clearanc
censor
time
death
plan
substudi
examin
cytokin
chemokin
immun
respons
serial
collect
blood
sampl
detail
protocol
substudi
publish
separ
safeti
outcom
assess
seriou
advers
event
report
follow
seriou
advers
event
document
time
studi
period
acut
pancreat
defin
two
follow
three
featur
abdomin
pain
consist
acut
pancreat
serum
lipas
amylas
least
three
time
greater
upper
limit
normal
characterist
find
acut
pancreat
contrastenhanc
comput
tomographi
magnet
reson
imag
b
elev
alt
fivefold
upper
normal
limit
c
anaphylaxi
bleed
diathesi
inr
without
anticoagul
therapi
follow
data
regard
advers
drug
reaction
assess
treat
team
record
daili
day
day
day
enrol
allerg
sensitivityhypersensit
reaction
includ
rash
urticaria
tongu
edema
bronchospasm
dyspnea
skin
necrosi
inject
site
b
gastrointestin
sign
symptom
includ
nausea
vomit
abdomin
pain
diarrhea
c
neurolog
symptom
includ
fatigu
headach
insomnia
psychosi
depress
mania
data
collect
baselin
current
ill
day
may
requir
telephon
interview
patient
next
kin
determin
patient
statu
accord
karnofski
perform
scale
scale
indic
normal
complaint
evid
diseas
indic
death
clinic
pharmacist
treat
physician
evalu
patient
time
enrol
daili
throughout
studi
period
day
identifi
interact
investig
treatment
drug
take
action
accordingli
tabl
summar
common
medic
may
interact
lopinavirritonavir
suggest
action
plan
elev
liver
enzym
common
mer
infect
due
liver
involv
diseas
base
analysi
histor
data
liver
enzym
elev
patient
treat
ribavirin
base
hiv
literatur
aminotransferas
elev
level
five
time
upper
limit
normal
occur
patient
take
lopinavir
ritonavircontain
antiretrovir
regimen
laboratori
abnorm
usual
asymptomat
selflimit
often
resolv
even
without
discontinu
drug
clinic
appar
hepatotox
due
lopinavirritonavir
occur
rare
symptom
jaundic
appear
usual
week
start
therapi
hepatotox
usual
selflimit
although
fatal
case
report
treat
team
discontinu
minim
concomit
use
medic
hepatotox
potenti
studi
intervent
suspend
subject
develop
defin
seriou
advers
event
occur
acut
pancreat
elev
alt
fivefold
upper
normal
limit
anaphylaxi
bleed
diathesi
event
review
least
two
peopl
third
necessari
blind
intervent
alloc
adjud
event
look
studi
dataclin
record
case
prematur
discontinu
treatment
aspect
studi
procedur
data
collect
laboratori
test
continu
patient
data
includ
intentiontotreat
analysi
break
blind
occur
event
treat
team
believ
strong
reason
know
studi
drug
alloc
discuss
studi
princip
investig
case
advers
event
necessit
emerg
unblind
report
seriou
advers
event
unexpect
medic
occurr
result
death
prolong
hospit
persist
signific
disabl
incapac
judg
causal
relat
studi
intervent
report
seriou
advers
event
institut
review
board
data
safeti
monitor
board
potenti
seriou
advers
event
trial
defin
includ
acut
pancreat
sever
elev
alt
fivefold
upper
normal
limit
anaphylaxi
bleed
diathesi
steer
committe
led
princip
investig
respons
overse
conduct
trial
provid
train
new
site
ensur
complianc
studi
procedur
address
challeng
occur
site
review
seriou
advers
event
formul
statist
analysi
plan
data
safeti
monitor
board
respons
review
report
regard
safeti
studi
patient
protocol
adher
may
make
recommend
continu
termin
studi
basi
result
interim
analysi
board
meet
begin
studi
interv
thereaft
need
sever
procedur
ensur
data
qualiti
protocol
complianc
undertaken
includ
train
session
studi
team
particip
center
prior
studi
commenc
startup
meet
site
either
site
remot
monitor
visit
close
studi
investig
drug
unit
king
abdullah
intern
medic
research
center
distribut
studi
medic
placebo
center
random
blind
perform
local
pharmaci
hospit
accord
procedur
describ
miracl
studi
approv
scientif
committe
institut
review
board
particip
site
regist
saudi
food
drug
author
sfda
studi
conduct
accord
ethic
principl
declar
helsinki
intern
council
harmonizationgood
clinic
practic
guidelin
inform
consent
obtain
patient
substitut
decisionmak
site
invistig
explain
object
trial
potenti
risk
benefit
patient
possibl
substitut
decisionmak
process
obtain
consent
compens
provid
enrol
trial
patient
person
data
deidentifi
data
center
store
secur
place
king
abdullah
intern
medic
research
center
riyadh
list
nameshospit
number
uniqu
studi
identif
id
kept
separ
locat
trial
data
associ
uniqu
subject
id
attach
baselin
clinic
demograph
characterist
summar
report
use
descript
statist
categor
variabl
report
number
percentag
compar
use
chisquar
test
fisher
exact
test
appropri
continu
variabl
report
mean
standard
deviat
median
interquartil
rang
compar
use
student
test
mannwhitney
u
test
appropri
primari
analysi
conduct
accord
intentiontotreat
principl
unadjust
perprotocol
analysi
perform
report
separ
primari
analysi
examin
differ
primari
outcom
group
report
absolut
risk
reduct
confid
interv
anticip
imbal
two
group
secondari
analysi
conduct
use
multipl
logist
regress
analysi
death
within
day
model
depend
variabl
set
baselin
variabl
strongli
believ
affect
outcom
merscov
infect
includ
independ
variabl
variabl
includ
minimum
age
communityacquir
versu
hospitalacquir
infect
mechan
ventil
center
sofa
score
multivari
analysi
also
includ
clinic
import
unequ
distribut
baselin
variabl
two
group
p
median
surviv
time
summar
report
use
kaplanmei
curv
compar
studi
group
use
logrank
test
statist
test
variabl
primari
outcom
perform
use
twosid
alpha
valu
denot
signific
level
patient
number
permit
eg
fewer
five
patient
subgroup
interest
stratifi
analysi
carri
follow
subgroup
patient
without
mechan
ventil
time
random
patient
differ
acut
physiolog
chronic
health
evalu
ii
apach
ii
diseasesever
score
time
random
stratifi
high
median
low
median
apach
ii
score
patient
receiv
receiv
vasopressor
time
random
patient
day
onset
symptom
enrol
patient
receiv
receiv
renal
replac
therapi
random
uncertainti
surround
recruit
rate
efficaci
level
treatment
trial
design
recurs
twostag
group
sequenti
random
trial
trial
design
initi
twostag
compon
two
interim
analys
one
final
analysi
fig
first
twostag
compon
design
determin
futil
stop
adjust
sampl
size
efficaci
stop
second
twostag
compon
design
determin
efficaci
stop
possibl
readjust
sampl
size
maintain
condit
power
final
analysi
classic
twogroup
design
requir
total
subject
subject
per
group
power
signific
level
onesid
test
detect
absolut
risk
reduct
mortal
among
subject
receiv
treatment
compar
control
group
trial
start
first
twostag
design
subject
subject
per
group
conduct
first
interim
analysi
total
subject
day
followup
reach
subject
per
group
total
sampl
size
need
classic
design
use
method
sum
stagewis
p
valu
determin
onesid
stop
boundari
first
twostag
design
list
tabl
first
interim
analysi
use
stagewis
p
valu
obtain
chisquar
test
differ
proport
determin
whether
trial
stop
futil
trial
continu
sampl
size
reestim
base
observ
effect
size
determin
use
follow
formula
assum
condit
power
base
estim
sampl
size
recalcul
condit
error
set
paramet
second
two
stage
second
interim
analysi
trial
continu
efficaci
sampl
size
readjust
made
base
previou
formula
new
boundari
calcul
finalstag
analysi
upon
complet
result
trial
plan
submit
peerreview
journal
authorship
follow
uniform
requir
manuscript
submit
biomed
journal
studi
first
random
control
trial
treatment
merscov
infect
although
type
studi
provid
best
method
determin
treatment
efficaci
diseas
outbreak
conduct
random
control
trial
logist
challeng
sinc
distribut
mer
case
sporad
unpredict
geograph
tempor
necessit
involv
sever
center
trial
ensur
adequ
recruit
requir
contribut
greatli
plan
administr
associ
trial
overcom
uncertainti
recruit
rate
efficaci
trial
treatment
design
trial
use
recurs
twostag
adapt
design
rel
new
method
group
sequenti
trial
approach
base
condit
error
principl
allow
continu
adjust
trial
paramet
use
data
observ
prior
stage
without
inflat
type
error
anoth
advantag
method
flexibl
set
time
number
need
interim
analys
flexibl
necessari
situat
recruit
rate
unpredict
sudden
flux
patient
recruit
could
happen
time
mani
emerg
infecti
diseas
includ
mer
patient
often
treat
therapeut
basi
minim
evid
exampl
patient
mer
treat
ribavirin
despit
lack
clinic
trial
explor
effect
treatment
combin
patient
includ
properli
design
studi
conclus
evid
might
gener
perform
trial
meet
critic
need
limit
studi
design
note
complet
blind
feasibl
unavail
appropri
placebo
therefor
studi
unblind
dose
nurs
dispens
pharmacist
otherwis
involv
patient
care
howev
blind
maintain
member
clinic
research
team
sporad
unpredict
natur
diseas
number
patient
site
may
low
account
aspect
work
iq
trial
site
manag
critic
revis
manuscript
import
intellectu
content
approv
final
version
publish
agreement
account
aspect
work
ab
trial
site
manag
critic
revis
manuscript
import
intellectu
content
approv
final
version
publish
agreement
account
aspect
work
ak
trial
site
manag
critic
revis
manuscript
import
intellectu
content
approv
final
version
publish
agreement
account
aspect
work
ss
trial
site
manag
critic
revis
manuscript
import
intellectu
content
approv
final
version
publish
agreement
account
aspect
work
jj
analyt
plan
critic
revis
manuscript
import
intellectu
content
approv
final
version
publish
agreement
account
aspect
work
raf
concept
design
critic
revis
manuscript
import
intellectu
content
approv
final
version
publish
agreement
account
aspect
work
fgh
concept
design
critic
revis
manuscript
import
intellectu
content
approv
final
version
publish
agreement
account
aspect
work
mah
analyt
plan
critic
revis
manuscript
import
intellectu
content
approv
final
version
publish
agreement
account
aspect
work
author
read
approv
final
manuscript
miracl
studi
approv
scientif
committe
institut
review
board
king
abdulaziz
medic
citi
regist
saudi
food
drug
author
sfda
approv
ethic
committe
sfda
secur
particip
site
start
patient
recruit
patient
meet
elig
criteria
substitut
decisionmak
patient
lack
decisionmak
capac
elig
patient
approach
obtain
inform
consent
enrol
applic
